Sensyne Partners With Excalibur To Improve Usability Of COVID-19 Tests

Sensyne has licensed its MagnifEye artificial intelligence technology to Excalibur Healthcare to improve the detection of COVID-19 infection at low viral loads.

magnifying glass with scan search concept and futuristic electronic technology background, transparent vector illustration
• Source: shutterstock.com

Sensyne Health plc, a clinical artificial intelligence start-up, has signed an exclusive license with diagnostic testing company Excalibur Healthcare Services to use Sensyne’s MagnifEye AI-based reading system in conjunction with Excalibur’s rapid lateral flow test kits.

The license, announced on 9 February, applies to COVID-19 indications and other areas,

More from AI

More from Digital Technologies